ACTIVE

FALIPHARMA

Export PDF

Financial year 2025 · closed on 31/12/2025

Net result

47,8 k €

+46.2% YoY

Gross margin

269,7 k €

+10.9% YoY

Equity

324,8 k €

+17.2% YoY

Workforce

3,0 ETP

0.0% YoY

What does FALIPHARMA do?

FALIPHARMA is a Private limited company incorporated in 1982. Its registered office is in Sambreville. It employs on average 3,0 ETP workers (FTE).

Legal situation

● Normal situation

BCE/KBO no. / VAT

BE 0422.990.373

Incorporation

31/08/1982

Legal form

Private limited company

Registered office

Rue J.J. Merlot(FAL) 3 box A
5060 Sambreville · WallonieSee on map

Contributed capital

19 000,00 €

Latest accounts

31/12/2025

Average workforce

3,0 ETP

Joint committees (1)

Signals

ProfitableSolid equityLow riskGood liquidityPositive cashflowPositive EBITDAHealthy social debts

View the BCE/KBO Public Search record →

Health score

Available with a Rovalta subscriptionTry for 7 days

Recommended credit limit

✦ Verdict · Analyst summary

Financials

Trend over 20 financial years

	2025		2024		2023		2022		2021		2020		2019		2018		2017		2016		2015		2014		2013		2012		2011		2010		2009		2008		2007		2006
Income statement
Gross margin	269,7 k €	+10.9%	243,3 k €	+13.9%	213,6 k €	-9.4%	235,7 k €	+17.4%	200,7 k €	+3.0%	195 k €	-6.4%	208,3 k €	-12.8%	238,7 k €	+23.5%	193,3 k €	-9.6%	213,7 k €	-16.3%	255,3 k €	+16.5%	219,2 k €	+21.8%	180 k €	-7.1%	193,8 k €	-9.6%	214,4 k €	+8.6%	197,4 k €	+26.9%	155,6 k €	-26.3%	211,1 k €	+19.3%	176,9 k €	-4.6%	185,6 k €
EBITDA	103,2 k €	+28.4%	80,4 k €	+35.6%	59,3 k €	-33.0%	88,4 k €	+48.4%	59,6 k €	-13.6%	69 k €	+3.6%	66,6 k €	-32.7%	99,1 k €	+71.7%	57,7 k €	-31.6%	84,4 k €	-32.0%	124,2 k €	+38.1%	90 k €	+71.8%	52,4 k €	-22.7%	67,8 k €	-31.1%	98,3 k €	+3.1%	95,3 k €	+87.2%	50,9 k €	-51.4%	104,9 k €	+33.4%	78,6 k €	-8.6%	86 k €
Operating result	79,7 k €	+38.3%	57,6 k €	+47.2%	39,2 k €	+37.5%	28,5 k €	+35.8%	21 k €	-4.9%	22 k €	+7.1%	20,6 k €	-63.6%	56,5 k €	+373%	12 k €	-42.2%	20,7 k €	-62.0%	54,4 k €	+184%	19,2 k €	+220%	-15,9 k €	-169%	23 k €	-32.9%	34,2 k €	+20.7%	28,4 k €	+268%	-16,9 k €	-145%	37,4 k €	+111%	17,8 k €	-40.7%	30 k €
Net result	47,8 k €	+46.2%	32,7 k €	+73.3%	18,9 k €	+146%	7,7 k €	+50.2%	5,1 k €	-26.1%	6,9 k €	+63.2%	4,2 k €	-87.7%	34,4 k €	+724%	-5,5 k €	-245%	3,8 k €	-89.7%	36,9 k €	+3188%	1,1 k €	+103%	-32,8 k €	-690%	5,6 k €	-64.6%	15,7 k €	+103%	7,7 k €	+120%	-38,1 k €	-257%	24,3 k €	+267%	6,6 k €	-68.4%	20,9 k €
Balance sheet
Equity	324,8 k €	+17.2%	277 k €	+14.1%	242,7 k €	+8.4%	223,8 k €	+3.2%	217 k €	+2.6%	211,5 k €	+3.4%	204,6 k €	+2.1%	200,3 k €	+20.7%	166 k €	-40.4%	278,6 k €	+1.4%	274,8 k €	+15.5%	238 k €	+0.5%	236,9 k €	-12.2%	269,6 k €	+2.1%	264,1 k €	+6.3%	248,4 k €	+3.2%	240,6 k €	-13.7%	278,8 k €	+9.5%	254,5 k €	+2.7%	247,9 k €
Total assets	732 k €	+7.4%	681,6 k €	+3.0%	661,9 k €	+4.9%	631 k €	-0.4%	633,4 k €	+23.1%	514,6 k €	-4.6%	539,4 k €	-3.9%	561,4 k €	+1.0%	556 k €	-18.0%	677,9 k €	-6.4%	724,6 k €	+1.1%	716,7 k €	+0.6%	712,7 k €	-7.0%	766,5 k €	+4.4%	734,3 k €	-7.2%	791,7 k €	+0.7%	785,8 k €	-1.8%	800,5 k €	-8.1%	871,1 k €	+46.7%	593,7 k €
Cash	243,3 k €	+20.3%	202,2 k €	+89.0%	107 k €	-47.6%	204,1 k €	+15.9%	176 k €	-11.4%	198,7 k €	+210%	64 k €	-34.9%	98,3 k €	+74.1%	56,5 k €	+90.6%	29,6 k €	-0.5%	29,8 k €	-25.5%	40 k €	+19.8%	33,4 k €	-17.7%	40,5 k €	+246%	11,7 k €	-63.7%	32,3 k €	+31.7%	24,5 k €	-65.8%	71,6 k €	-41.3%	121,9 k €	+520%	19,7 k €
Debts	387,6 k €	-1.8%	394,7 k €	-3.6%	409,5 k €	+3.1%	397,1 k €	-2.3%	406,5 k €	+38.0%	294,6 k €	-9.2%	324,5 k €	-7.9%	352,5 k €	-7.0%	379,1 k €	-2.4%	388,4 k €	-11.4%	438,3 k €	-6.2%	467,2 k €	+0.6%	464,2 k €	-4.2%	484,8 k €	+6.1%	457 k €	-12.0%	519,3 k €	-1.1%	525 k €	+1.5%	517,5 k €	-15.0%	609,1 k €	+78.9%	340,5 k €
Other
Workforce	3,0 ETP	0.0%	3,0 ETP	0.0%	3,0 ETP	0.0%	3,0 ETP	-6.3%	3,2 ETP	-100.0%	120 124,4 ETP	+3753788%	3,2 ETP	0.0%	3,2 ETP	0.0%	3,2 ETP	0.0%	3,2 ETP	0.0%	3,2 ETP	0.0%	3,2 ETP	0.0%	3,2 ETP	0.0%	3,2 ETP	0.0%	3,2 ETP	+18.5%	2,7 ETP	-12.9%	3,1 ETP	0.0%	3,1 ETP	-3.1%	3,2 ETP	+3.2%	3,1 ETP

Estimate

Indicative valuation

As an indication, this company is worth

between 500 k€ and 1 M€

See the valuation

Governance

Board of directors

Seen on filing of 31/12/2025 · 2 active · 5 ended

Active mandates

Jaroline Pharma

Director · since 01 janvier 2026 · 1023.796.101

Represented by RUTH CELINE

Active

MARIE SCAILQUIN ANNE

Director · since 01 janvier 2015

Active

Ended mandates

CELINE RUTH

Director · since 01 janvier 2015

Ended

Anne SCAILQUIN

Manager

Ended

ANNE SCAILQUIN

Director

Ended

CELINE RUTH

Director

Ended

At this address

Other companies at this address

Company	CBE no.
BDG NAMUR● Active	0431.828.063

Annual accounts

Full financial information

	2025	2024	2023	2022	2021	2020
Type of account	Abridged model	Abridged model	Abridged model	Abridged model	Abridged model	Abridged model
Start of the financial year	01/01/2025	01/01/2024	01/01/2023	01/01/2022	01/01/2021	01/01/2020
Closing of the financial year	31/12/2025	31/12/2024	31/12/2023	31/12/2022	31/12/2021	31/12/2020
Length of the financial year	12 months	12 months	12 months	12 months	12 months	12 months
Filing date	24/07/2026	19/08/2025	21/08/2024	13/07/2023	06/07/2022	09/08/2021
General meeting	05/05/2026	06/05/2025	07/05/2024	02/05/2023	03/05/2022	04/05/2021
Currency of the financial year	EUR	EUR	EUR	EUR	EUR	EUR
NBB quality label	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls

Ratios

Financial ratios

Looking for more information about this company?

Try for 7 days

Filings

Annual accounts filings

20 filings with the NBB

Model	Closing	General meeting	Filed	Language	Document
Abridged model	31/12/2025	05/05/2026	24/07/2026	French	PDF
Abridged model	31/12/2024	06/05/2025	19/08/2025	French	PDF
Abridged model	31/12/2023	07/05/2024	21/08/2024	French	PDF
Abridged model	31/12/2022	02/05/2023	13/07/2023	French	PDF
Abridged model	31/12/2021	03/05/2022	06/07/2022	French	PDF
Abridged model	31/12/2020	04/05/2021	09/08/2021	French	PDF
Abridged model	31/12/2019	05/05/2020	14/08/2020	French	PDF
Abridged model	31/12/2018	07/05/2019	16/09/2019	French	PDF
Abridged model	31/12/2017	02/05/2018	29/08/2018	French	PDF
Abridged model	31/12/2016	02/05/2017	26/07/2017	French	PDF
Abridged model	31/12/2015	03/05/2016	02/08/2016	French	PDF
Abridged model	31/12/2014	05/05/2015	18/08/2015	French	PDF
Abridged model	31/12/2013	06/05/2014	28/07/2014	French	PDF
Abridged model	31/12/2012	07/05/2013	02/07/2013	French	PDF
Abridged model	31/12/2011	02/05/2012	30/08/2012	French	PDF
Abridged model	31/12/2010	02/08/2011	10/08/2011	French	PDF
Abridged model	31/12/2009	04/05/2010	30/09/2010	French	PDF
Abridged model	31/12/2008	05/05/2009	05/08/2009	French	PDF
Abridged model	31/12/2007	06/05/2008	29/08/2008	French	PDF
Abridged model	31/12/2006	02/05/2007	24/07/2007	French	PDF

Estimate

Indicative valuation

Order of magnitude

As an indication, this company is worth

between 500 k€ and 1 M€

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan

Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Governance

Board of directors

Seen on filing of 31/12/2025 · 2 active · 5 ended

Active mandates

Jaroline Pharma

Director · since 01 janvier 2026 · 1023.796.101

Represented by RUTH CELINE

Active

MARIE SCAILQUIN ANNE

Director · since 01 janvier 2015

Active

Ended mandates

CELINE RUTH

Director · since 01 janvier 2015

Ended

Anne SCAILQUIN

Manager

Ended

ANNE SCAILQUIN

Director

Ended

CELINE RUTH

Director

Ended

Shareholders

Ownership and network

Looking for more information about this company?

Try for 7 days

Belgian Official Gazette

Belgian Official Gazette publications

Registered office04/08/2026
SIEGE SOCIAL
PDF
Mandates10/02/2026
SIEGE SOCIAL - DEMISSIONS, NOMINATIONS
PDF
Mandates29/11/2021
MODIFICATION FORME JURIDIQUE - DEMISSIONS, NOMINATIONS
PDF
Mandates20/02/2015
DEMISSIONS, NOMINATIONS
PDF
Registered office13/03/2007
SIEGE SOCIAL
PDF
Other12/03/2004
RUBRIQUE CONSTITUTION (NOUVELLE PERSONNE MORALE, OUVERTURE SUCCURSALE, ETC...)
PDF

Source: Belgian Official Gazette

Competition

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

2025
Annual accounts 202547,8 k €↑
2024
Annual accounts 202432,7 k €↑
2023
Annual accounts 202318,9 k €↑
2022
Annual accounts 20227,7 k €↑
2021
Annual accounts 20215,1 k €↓
2020
Annual accounts 20206,9 k €↑
2019
Annual accounts 20194,2 k €↓
2018
Annual accounts 201834,4 k €↑
2017
Annual accounts 2017-5,5 k €↓
2016
Annual accounts 20163,8 k €↓
2015
Annual accounts 201536,9 k €↑
2014
Annual accounts 20141,1 k €↑
2013
Annual accounts 2013-32,8 k €↓
2012
Annual accounts 20125,6 k €↓
2011
Annual accounts 201115,7 k €↑
2010
Annual accounts 20107,7 k €↑
2009
Annual accounts 2009-38,1 k €↓
2008
Annual accounts 200824,3 k €↑
2007
Annual accounts 20076,6 k €↓
2006
Annual accounts 200620,9 k €
31/08/1982
IncorporationPrivate limited company

10/15	1 240 000	1 180 000	1 050 000
70	8 630 000	8 120 000	7 940 000
9904	412 000	388 000	301 000
17/49	2 970 000	3 140 000	3 380 000
9087	24,3	23,1	21,8

FALIPHARMA

Overview

What does FALIPHARMA do?

Trend over 20 financial years

Indicative valuation

Board of directors

Other companies at this address

Financials

Full financial information

Financial ratios

Annual accounts filings

Valuation

Indicative valuation

Directors & structure

Board of directors

Ownership and network

Publications

Belgian Official Gazette publications

Similar companies

Similar companies

Timeline